9 results
10-K
2023 FY
CRGX
CARGO Therapeutics Inc
21 Mar 24
Annual report
4:21pm
(a molecule that typically interacts with a receptor) expressed on the surface of tumor cells, such as CD58. Tumor cells can escape CAR T-cell … and T-cell), including de novo disease, suggesting a potential utility for our CD2 platform technology to mitigate immune escape in future therapies. Our
8-K
EX-99.1
CRGX
CARGO Therapeutics Inc
8 Jan 24
Regulation FD Disclosure
6:11am
escape (e.g., CD19) Target Alt Antigen or Multi-specific CAR designs Loss of costimulation (e.g., CD58) CAR-Engineered, CD2 technology Immune rejection
424B4
CRGX
CARGO Therapeutics Inc
13 Nov 23
Prospectus supplement with pricing info
4:31pm
cells can escape CAR T-cell destruction by downregulating the expression of ligands
for the costimulatory receptors. Alteration of CD58 expression … escape, which occurs when a tumor mutates to escape the patient’s immune system. Our CD2 platform creates constructs that couple CD2 signaling
S-1
CRGX
CARGO Therapeutics Inc
20 Oct 23
IPO registration
4:07pm
, with their cognate ligands (a molecule that typically interacts with that receptor) expressed on the surface of tumor cells, such as CD58. Tumor cells can escape CAR … ), including de novo disease, suggesting a potential utility for our CD2 platform technology in future therapies to mitigate immune escape, which
DRS/A
dzfmz19sdkr1qyt
4 Oct 23
Draft registration statement (amended)
12:00am
DRSLTR
d63ajl4uny is
4 Oct 23
Correspondence regarding draft registration statement
12:00am
UPLOAD
vx2tqfn
28 Sep 23
Letter from SEC
12:00am
DRS
0en irkkg6
1 Sep 23
Draft registration statement
12:00am
- Prev
- 1
- Next